Trevi Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Trevi Therapeutics, Inc. (TRVI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $6.73 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $6.74, a 183.19% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.38.
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.62, a 13.29% increase year-over-year.
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.43.
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $3.38, a 43.22% increase from fiscal 2024.
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $2.36, a 33.33% increase from fiscal 2023.
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $1.77, a 50.70% decline from fiscal 2022.
- Trevi Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $3.59, a 16.51% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.73 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $6.74 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $3.38 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $3.35 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $2.38 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $2.38 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $2.36 10-K · filed 2025-03-18 | |||
| 2024-09-30 | $2.25 10-Q · filed 2024-11-06 | |||
| 2023-12-31 | $1.77 10-K · filed 2024-03-20 | |||
| 2023-09-30 | $1.77 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.62 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $1.62 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $3.59 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $3.59 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $4.21 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $1.43 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $4.30 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $4.39 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $4.57 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $7.77 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $10.00 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $10.00 10-Q · filed 2020-08-13 | |||
| 2019-12-31 | $8.60 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $7.67 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | $7.67 10-Q · filed 2019-08-12 | |||
| 2019-03-31 | $3.04 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |